Dimerix Limited · ASX:DXB
Dimerix — Investor Presentation (February 2016)
14 slides from Dimerix's investor presentation, Feb 9, 2016
Slide 1: A clinical stage biotechnology business with a development pipeline
For personal use only A clinical stage biotechnology business with a development pipeline Investor Update February 2016
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Dimerix Limited (“Dimerix” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessa
Slide 3: Dimerix Overview
Dimerix Overview For personal use only Company Assets (Dimerix) Corporate Snapshot A globally focused drug development company ASX Code: DXB (formerly SBN) with a portfolio of new therapies for unmet medical Share Price: $.005 needs Market cap: $6.6m Lead Program: DMX-200 in Phase II clinical trials
Slide 4: Board
Board For personal use only Executive Chairman: Dr James Williams • 15 years experience starting, funding, running and exiting biotechnology companies BSc(Hons), PhD, MBA • Co-founder of Dimerix and iCeutica (acquired in 2011 and now with 3 FDA drug approvals) • Co-founder and Investment Director of
Slide 5: Management and Advisors
Management and Advisors For personal use only General Manager: Ms Kathy Harrison • Experienced Biotech Executive: AMRAD, Cytopia Research Pty Ltd, Phosphagenics Limited MSc, Cert.Gov.(Prac), FIPTA • Registered Patent and Trademark Attorney Scientific Advisors: Assoc. Prof Kevin Pfleger • Inventor Di
Slide 6: Chronic Kidney Disease and FSGS
Chronic Kidney Disease and FSGS For personal use only A major unmet clinical need with limited treatment options ⊚ Chronic Kidney Disease (CKD): a large and complex group of disease ultimately leading to kidney failure, dialysis and transplant. ⊚ ~26 million people in the US alone ⊚ Focal Segmental
Slide 7: DMX200 – A new treatment for CKD
DMX200 – A new treatment for CKD For personal use only ⊚ DMX-200: A combination of Irbesartan (Irb, angiotensin II receptor type 1 (AT1) antagonist) and propagermanium (PPG, Chemokine Receptor 2 (CCR2) antagonist). ⊚ Irb: Off-patent blockbuster drug used primarily for treatment of high blood pressur
Slide 8: DMX200 – Clinical trial progress
DMX200 – Clinical trial progress For personal use only ⊚ Treatment of Proteinuria in CKD patients ⊚ Study design: Fixed dose combination of Irbesartan + Propagermanium ⊚ Enrolment: Up to 60 patients in two Parts ⊚ Part A: Dose escalation – Up to 5 doses x 1 month, then 2 further months at maximal do
Slide 9: Companies in CKD space
Companies in CKD space For personal use only o Acthar gel (injection only, steroid) o Phase I asset for treating kidney o Completed Phase II for CCX140 fibrosis in diabetic nephropathy – a o Approved in 2011 for treating CCR2 antagonist proteinuria in Nephrotic o Pursuing FSGS as initial Syndrome in
Slide 10: Dimerix – Not a single asset play
Dimerix – Not a single asset play For personal use only DMX-200 ⊚Potential utility in other indications ⊚Pre-clinical animal studies underway for liver disease – a major global health problem ⊚ Results expected Q3 2016 Receptor-HIT: A powerful discovery engine ⊚Enables identification of new therapeu
Slide 11: Value proposition of GPCR discovery platforms
Value proposition of GPCR discovery platforms For personal use only o Phase 1b plus multiple pre- o Early phase III and two phase II o Phase III and phase II assets clinical leads assets o Acquired by Celgene Jul 2015 o Acquired by Sosei Feb 2015 for o Nasdaq Listed (TRVN): Market for US$6 billion U
Slide 12: Core Intellectual Property
Core Intellectual Property For personal use only Combination Therapy: PCT Number: AU2012/000014 International Filing 11 January 2012 Date: Status: Granted in Australia, examination progressing EU, accelerating in US through Patent Prosecution Highway Applicant: Dimerix Bioscience Pty Ltd Inventors:
Slide 13: Summary
Summary For personal use only ⊚ Clinical stage (phase II) biotechnology company focused in an area of high unmet clinical need ⊚ Orphan Drug Designation secured in the US ⊚ On-track to report initial safety and efficacy data from DMX-200 in Q2/Q3 2016 ⊚ Preparing to accelerate US trials through pre-
Slide 14: Further Information
For personal use only Further Information James Williams, Executive Chairman +61 409 050 519 james@dimerix.com Dimerix Bioscience Limited ACN 112 223 417 www.dimerix.com